Bristol-Myers Squibb (BMS), US

November 3, 2010, Simcere and BMS established a strategic partnership to research and develop BMS-817378 for the potential treatment of tumors. Simcere receives exclusive right to develop and commercialize BMS-817378 in China while Bristol-Myers Squibb retains exclusive rights in all other markets. This unique arrangement represents a creative approach to accelerate a preclinical oncology compound to clinical proof-of-concept by leveraging the complementary strengths of a premier Chinese pharmaceutical company and a global pharmaceutical company. This partnership also represents a novel model for Sino-US cooperation. 

June 14, 2013, Simcere and BMS expanded their strategic relationship to co-develop and co-commercialize Orencia® SC (abatacept) in China. Orencia SC is already on the market for the treatment of rheumatoid arthritis in the U.S., Europe and Japan. Simcere will perform and fund all development and regulatory activities required to obtain market approval for Orencia SC in China. The companies will share responsibility for commercializing Orencia and related profits and losses.

BMS is a top-ten global biopharmaceutical company with a long and successful history. With its 54,000 employees in 120 countries, BMS is a diversified and R&D-oriented enterprise with annual sales of $15 billion.

© Copyright 2016 www.simcere.com All Rights Reserved.